📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. (2023)

First Author: Daver NG

Attributed to: University of Oxford – Confidence in Concept 2019 funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1200/jco.22.02604

PubMed Identifier: 37703506

Publication URI: http://europepmc.org/abstract/MED/37703506

Type: Journal Article/Review

Volume: 41

Parent Publication: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Issue: 31

ISSN: 0732-183X